MedTrace Logo

ARIA (Atacand Renoprotection In NephropAthy Pt.)

NCT00573430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2011-08-23

Study results available
· View outcomes & findings →

Summary

To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment

Conditions

  • Non-diabetic Nephropathy With Hypertension

Interventions

DRUG

Candesartan Cilexetil

8 mg oral once daily dose

DRUG

Candesartan Cilexetil

16 mg oral once daily dose

DRUG

Candesartan Cilexetil 32mg

32 mg oral once daily dose

Sponsors & Collaborators

Principal Investigators

  • Da Suk Han · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573430 on ClinicalTrials.gov